39630-24-5

Basic information

• Product Name: (2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE
• Synonyms: ASISCHEM N43299;BUTTPARK 51\02-36;AKOS BBB/054;2-(MORPHOLIN-4-YLCARBONYL)ANILINE;[2-(MORPHOLIN-4-YLCARBONYL)PHENYL]AMINE;(2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE;2-(4-MORPHOLINYLCARBONYL)ANILINE;AKOS BBV-014494
• CAS NO: 39630-24-5
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.24
• Mol File: 39630-24-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 411.6°C at 760 mmHg
• Flash Point: 202.7°C
• Appearance: /
• Density: 1.228g/cm³
• Vapor Pressure: 5.52E-07mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: (2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(39630-24-5)
• EPA Substance Registry System: (2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(39630-24-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 39630-24-5(Hazardous Substances Data)

Usage

General Description

"(2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE" is a chemical compound that consists of a morpholine ring with a phenyl ring attached to one of the nitrogen atoms and a ketone group attached to the morpholine ring. It has the molecular formula C12H15N3O2 and a molar mass of 233.27 g/mol. The compound is commonly used in the pharmaceutical and research industries due to its potential biological activities. It has been studied for its potential as an antinociceptive and anti-inflammatory agent, as well as its inhibitory effects on enzymes such as protein kinase and aromatase. Additionally, it has been investigated for its potential use in the treatment of neurological disorders and cancer. Overall, "(2-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE" is a versatile and important chemical compound with potential applications in various fields.

InChI:InChI=1/C11H14N2O2/c12-10-4-2-1-3-9(10)11(14)13-5-7-15-8-6-13/h1-4H,5-8,12H2

Upstream product

• 110-91-8 morpholine 
• 118-48-9 isatoic anhydride 
• 26162-89-0 morpholin-4-yl-(2-nitrophenyl)methanone 
• 118-92-3 anthranilic acid 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 21563-73-5 2-aminobenzoyl chloride 

Downstream Products

• 56415-52-2 N⁴-hydroxy-N¹-[2-(morpholine-4-carbonyl)-phenyl]-2-pentyl-succinamide 
• 39630-05-2 5-oxo-1-phenyl-pyrrolidine-3-carboxylic acid 2-(morpholine-4-carbonyl)-anilide 
• 31075-60-2 [2-(morpholine-4-carbonyl)-phenyl]-oxalamic acid ethyl ester 
• 80953-64-6 (3-methoxymorpholino)(phenyl)methanone 
• 31075-66-8 N-(2-dimethylamino-ethyl)-N'-[2-(morpholine-4-carbonyl)-phenyl]-oxalamide 

Relevant articles and documents

Visible-light, metal-free α-amino C(sp3)-H activation through 1,5-hydrogen migration: A concise method for the preparation of bis(indolyl)alkanes

A photoredox catalytic, metal-free method for C-H functionalization α to amines directly leads to the formation of bis(indolyl)alkane products in good to excellent yields. This transformation hinges on a smooth 1,5-hydrogen migration to an aryl radical in

Synthesis, antimicrobial evaluation, ot-QSAR and mt-QSAR studies of 2-amino benzoic acid derivatives

A series of 2-amino benzoic acid derivatives (1-28) were synthesized and evaluated for their in vitro antimicrobial activity against the panel of Gram positive, Gram negative bacterial and fungal strains. The results of antimicrobial studies indicated that, in general, the synthesized compounds were found to be bacteriostatic and fungistatic in action. QSAR studies performed by the development of one target and multi target models indicated that multi-target model was effective in describing the antimicrobial activity as well demonstrated the effect of structural parameters viz. LUMO, 3χv and W on antimicrobial activity of 2-amino benzoic acid derivatives. Springer Science+Business Media, LLC 2010.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.